Log in
Enquire now
Epsilogen

Epsilogen

Developer of immunoglobulin E (IgE) antibodies to treat cancer.

OverviewStructured DataIssuesContributors

Contents

epsilogen.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
‌
Deep Tech
Biotechnology
Biotechnology
Pharmaceutical industry
Pharmaceutical industry
Manufacturing
Manufacturing
Genetics
Genetics
Health technology
Health technology
Location
United Kingdom
United Kingdom
London
London
0
B2X
B2B
B2B
CEO
‌
Tim Wilson
Pitchbook URL
pitchbook.com/profiles...183107-89
Number of Employees (Ranges)
11 – 50
Email Address
Phone Number
Full Address
London BioScience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK0
Investors
British Patient Capital
British Patient Capital
‌
3B Future Health Fund
ALSA Ventures
ALSA Ventures
0
AlbionVC
AlbionVC
Novartis Venture Fund
Novartis Venture Fund
Epidarex Capital
Epidarex Capital
Founded Date
January 1, 2016
Total Funding Amount (USD)
117,300,000
Latest Funding Round Date
September 9, 2024
CFO
‌
Nick Cherry
Latest Funding Type
Series B
Series B
Country
United Kingdom
United Kingdom
Headquarters
London
London

Other attributes

Latest Funding Round Amount (USD)
16,500,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Epsilogen

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.